Compare IMKTA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | ARDX |
|---|---|---|
| Founded | 1963 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2014 |
| Metric | IMKTA | ARDX |
|---|---|---|
| Price | $69.81 | $6.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $10.65 |
| AVG Volume (30 Days) | 114.5K | ★ 3.7M |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $5,334,032,609.00 | $398,234,000.00 |
| Revenue This Year | N/A | $22.77 |
| Revenue Next Year | N/A | $28.02 |
| P/E Ratio | $15.65 | ★ N/A |
| Revenue Growth | N/A | ★ 58.12 |
| 52 Week Low | $58.92 | $3.21 |
| 52 Week High | $78.59 | $6.78 |
| Indicator | IMKTA | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 65.07 |
| Support Level | $67.92 | $5.53 |
| Resistance Level | $70.83 | $6.40 |
| Average True Range (ATR) | 1.51 | 0.34 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 32.21 | 87.23 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.